Cerenis Therapeutics, a biopharmaceutical company focused on discovering and developing novel HDL therapies, announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute coronary syndromes. Results of the completed study provide evidence that the investigational therapy was safe and well-tolerated at all dose levels evaluated, including those intended for future clinical development.
The Phase 1 randomized, double-blind, placebo-controlled, cross-over, single rising dose study of 32 healthy dyslipidemic human volunteers, was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single intravenous infusions of CER-001. In this study, each subject received dosages up to 45 mg/kg and placebo in a two period crossover design. No drug related adverse events were reported for CER-001, and cholesterol mobilization was observed at dose levels of 2mg/kg and higher.
The results from this study were consistent with pre-clinical findings in demonstrating evidence of dose-related cholesterol mobilization, as well as evidence of substantial increases in HDL-cholesterol levels. Because of these properties, we believe that administration of CER-001 may promote reverse cholesterol transport and stimulate cholesterol removal in patients.
"These positive results represent an important milestone for the CER-001 program and Cerenis' approach to developing potent HDL mimetics." said Jean-Louis Dasseux, CEO of Cerenis. "The data are strongly supportive of continued clinical development of CER-001 as a treatment for patients with high-risk atherosclerosis, including acute coronary syndromes."
About CER-001
CER-001, a complex of human ApoA-I and phospholipids, is being developed for the treatment of patients with acute coronary syndromes. CER-001 is designed to mimic HDL, the "good" cholesterol, to promote the removal of excess cholesterol and other lipids from artery walls and enhance reverse lipid transport.
Source
Cerenis Therapeutics